In a latest development, Stifel analyst David Grossman has maintained his 'Buy' rating for OptimizeRx (OPRX, Financial). This announcement follows a decision to raise the price target from USD 12.50 to USD 16.00, reflecting a significant increase of 28%.
OptimizeRx (OPRX, Financial) continues to be positioned as a strong investment opportunity, as indicated by the current 'Buy' rating. The adjustment in price target underscores the analyst's positive outlook on the company's future performance in the stock market.
Investors in OptimizeRx (OPRX, Financial) may find this update encouraging, as the raised price target signifies a potential upward trend in the stock's value. This reassessment aligns with broader market expectations and highlights the company's strategic advancements.
The analysis by Stifel and the maintained rating suggest a continued confidence in OptimizeRx’s (OPRX, Financial) capability to achieve growth benchmarks and deliver shareholder value.
For more updates on OptimizeRx (OPRX, Financial), investors are encouraged to monitor market developments and analyst insights to make informed decisions.
Wall Street Analysts Forecast
Based on the one-year price targets offered by 6 analysts, the average target price for OptimizeRx Corp (OPRX, Financial) is $16.17 with a high estimate of $22.00 and a low estimate of $11.00. The average target implies an upside of 13.21% from the current price of $14.28. More detailed estimate data can be found on the OptimizeRx Corp (OPRX) Forecast page.
Based on the consensus recommendation from 7 brokerage firms, OptimizeRx Corp's (OPRX, Financial) average brokerage recommendation is currently 1.9, indicating "Outperform" status. The rating scale ranges from 1 to 5, where 1 signifies Strong Buy, and 5 denotes Sell.
Based on GuruFocus estimates, the estimated GF Value for OptimizeRx Corp (OPRX, Financial) in one year is $17.78, suggesting a upside of 24.51% from the current price of $14.28. GF Value is GuruFocus' estimate of the fair value that the stock should be traded at. It is calculated based on the historical multiples the stock has traded at previously, as well as past business growth and the future estimates of the business' performance. More detailed data can be found on the OptimizeRx Corp (OPRX) Summary page.
